nodes	percent_of_prediction	percent_of_DWPC	metapath
Vapreotide—TACR1—Spinal Cord Injury—AIF1—systemic scleroderma	0.123	0.123	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.06	0.06	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—SELP—systemic scleroderma	0.0534	0.0534	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—RHOB—systemic scleroderma	0.0499	0.0499	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.0409	0.0409	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.0322	0.0322	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.0257	0.0257	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL1A—systemic scleroderma	0.0253	0.0253	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.0239	0.0239	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.0221	0.0221	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.0203	0.0203	CbGpPWpGaD
Vapreotide—TACR1—G alpha (q) signalling events—EDN1—systemic scleroderma	0.0176	0.0176	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—CCL2—systemic scleroderma	0.0174	0.0174	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.0174	0.0174	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.0164	0.0164	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.0161	0.0161	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.0158	0.0158	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.0151	0.0151	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.0148	0.0148	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—RHOB—systemic scleroderma	0.0135	0.0135	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.0134	0.0134	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL1B—systemic scleroderma	0.0132	0.0132	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—RHOB—systemic scleroderma	0.0125	0.0125	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—MMP9—systemic scleroderma	0.0125	0.0125	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—RHOB—systemic scleroderma	0.0123	0.0123	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—EDN1—systemic scleroderma	0.0122	0.0122	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.0119	0.0119	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.0117	0.0117	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—RHOB—systemic scleroderma	0.0113	0.0113	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—EDN1—systemic scleroderma	0.0113	0.0113	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.011	0.011	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.0106	0.0106	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—TGFB1—systemic scleroderma	0.0103	0.0103	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.0101	0.0101	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—RHOB—systemic scleroderma	0.00984	0.00984	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—SMAD7—systemic scleroderma	0.00939	0.00939	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—RHOB—systemic scleroderma	0.00893	0.00893	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—EDN1—systemic scleroderma	0.00889	0.00889	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—SMAD7—systemic scleroderma	0.00867	0.00867	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCL2—systemic scleroderma	0.00836	0.00836	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.00798	0.00798	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCL2—systemic scleroderma	0.00772	0.00772	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—RHOB—systemic scleroderma	0.00726	0.00726	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—EDN1—systemic scleroderma	0.00691	0.00691	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—HSPG2—systemic scleroderma	0.00685	0.00685	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—SMAD7—systemic scleroderma	0.00682	0.00682	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—RHOB—systemic scleroderma	0.0067	0.0067	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CSK—systemic scleroderma	0.00662	0.00662	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—EDN1—systemic scleroderma	0.00638	0.00638	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—HSPG2—systemic scleroderma	0.00632	0.00632	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—EDN1—systemic scleroderma	0.00628	0.00628	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CSK—systemic scleroderma	0.00611	0.00611	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCL2—systemic scleroderma	0.00608	0.00608	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—EDN1—systemic scleroderma	0.00579	0.00579	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—RHOB—systemic scleroderma	0.00528	0.00528	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—EDN1—systemic scleroderma	0.00502	0.00502	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—HSPG2—systemic scleroderma	0.00498	0.00498	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CSK—systemic scleroderma	0.00481	0.00481	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—EDN1—systemic scleroderma	0.00456	0.00456	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCL2—systemic scleroderma	0.00429	0.00429	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCL2—systemic scleroderma	0.00396	0.00396	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—EDN1—systemic scleroderma	0.00371	0.00371	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—EDN1—systemic scleroderma	0.00342	0.00342	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCL2—systemic scleroderma	0.00312	0.00312	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—EDN1—systemic scleroderma	0.00269	0.00269	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCL2—systemic scleroderma	0.00254	0.00254	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCL2—systemic scleroderma	0.00234	0.00234	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—NOS3—systemic scleroderma	0.00226	0.00226	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—NOS3—systemic scleroderma	0.00209	0.00209	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCL2—systemic scleroderma	0.00184	0.00184	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—MMP9—systemic scleroderma	0.00181	0.00181	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—MMP9—systemic scleroderma	0.00167	0.00167	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—NOS3—systemic scleroderma	0.00164	0.00164	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—TGFB1—systemic scleroderma	0.00149	0.00149	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—TGFB1—systemic scleroderma	0.00138	0.00138	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—MMP9—systemic scleroderma	0.00132	0.00132	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—TGFB1—systemic scleroderma	0.00109	0.00109	CbGpPWpGaD
